| pubmed-article:21392921 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21392921 | lifeskim:mentions | umls-concept:C0039286 | lld:lifeskim |
| pubmed-article:21392921 | lifeskim:mentions | umls-concept:C0870883 | lld:lifeskim |
| pubmed-article:21392921 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:21392921 | lifeskim:mentions | umls-concept:C0449851 | lld:lifeskim |
| pubmed-article:21392921 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:21392921 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:21392921 | lifeskim:mentions | umls-concept:C1517586 | lld:lifeskim |
| pubmed-article:21392921 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:21392921 | pubmed:dateCreated | 2011-4-4 | lld:pubmed |
| pubmed-article:21392921 | pubmed:abstractText | A comprehensive overview is presented of currently known phase I metabolites of tamoxifen consisting of their systematic name and molecular structure. Reference standards are utilized to elucidate the MS(n) fragmentation patterns of these metabolites using a linear ion trap mass spectrometer. UV-absorption spectra are recorded and absorption maxima are defined. Serum extracts from ten breast cancer patients receiving 40mg tamoxifen once daily were qualitatively analyzed for tamoxifen phase I metabolites using a liquid chromatography-tandem mass spectrometry set-up. In total, 19 metabolites have been identified in these serum samples. Additionally a synthetic method for the preparation of the putative metabolite 3',4'-dihydroxytamoxifen is described. | lld:pubmed |
| pubmed-article:21392921 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21392921 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21392921 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21392921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21392921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21392921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21392921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21392921 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21392921 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21392921 | pubmed:issn | 1873-264X | lld:pubmed |
| pubmed-article:21392921 | pubmed:author | pubmed-author:BeijnenJ HJH | lld:pubmed |
| pubmed-article:21392921 | pubmed:author | pubmed-author:RosingHH | lld:pubmed |
| pubmed-article:21392921 | pubmed:author | pubmed-author:SchinkelA HAH | lld:pubmed |
| pubmed-article:21392921 | pubmed:author | pubmed-author:BrunsveldLL | lld:pubmed |
| pubmed-article:21392921 | pubmed:author | pubmed-author:SchellensJ... | lld:pubmed |
| pubmed-article:21392921 | pubmed:author | pubmed-author:TeunissenS... | lld:pubmed |
| pubmed-article:21392921 | pubmed:author | pubmed-author:SeoaneM... | lld:pubmed |
| pubmed-article:21392921 | pubmed:copyrightInfo | Copyright © 2011 Elsevier B.V. All rights reserved. | lld:pubmed |
| pubmed-article:21392921 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21392921 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:21392921 | pubmed:volume | 55 | lld:pubmed |
| pubmed-article:21392921 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21392921 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21392921 | pubmed:pagination | 518-26 | lld:pubmed |
| pubmed-article:21392921 | pubmed:meshHeading | pubmed-meshheading:21392921... | lld:pubmed |
| pubmed-article:21392921 | pubmed:meshHeading | pubmed-meshheading:21392921... | lld:pubmed |
| pubmed-article:21392921 | pubmed:meshHeading | pubmed-meshheading:21392921... | lld:pubmed |
| pubmed-article:21392921 | pubmed:meshHeading | pubmed-meshheading:21392921... | lld:pubmed |
| pubmed-article:21392921 | pubmed:meshHeading | pubmed-meshheading:21392921... | lld:pubmed |
| pubmed-article:21392921 | pubmed:meshHeading | pubmed-meshheading:21392921... | lld:pubmed |
| pubmed-article:21392921 | pubmed:meshHeading | pubmed-meshheading:21392921... | lld:pubmed |
| pubmed-article:21392921 | pubmed:meshHeading | pubmed-meshheading:21392921... | lld:pubmed |
| pubmed-article:21392921 | pubmed:meshHeading | pubmed-meshheading:21392921... | lld:pubmed |
| pubmed-article:21392921 | pubmed:meshHeading | pubmed-meshheading:21392921... | lld:pubmed |
| pubmed-article:21392921 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21392921 | pubmed:articleTitle | Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques. | lld:pubmed |
| pubmed-article:21392921 | pubmed:affiliation | Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands. Bas.Teunissen@slz.nl | lld:pubmed |
| pubmed-article:21392921 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21392921 | pubmed:publicationType | Review | lld:pubmed |
